A Phase 3, Randomized, Placebo-Controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
Trial Number
2022-02540-42 (EudraCT Number)Contact Person
Status
Recruiting
Disease Site
Endometrial
Lead Cooperative Group
Participating Groups
GOG-F
MITO
MaNGO
CEEGOG
ISGO
GEICO
NOGGO